PolQi1

PolQi1 is a selective inhibitor targeting the Polθ domain of DNA polymerase. PolQi1 inhibits the Polθ-mediated microhomology end joining (TMEJ/alt-EJ) pathway, reducing insertion/deletion (Indels) and imprecise editing events during DNA repair. PolQi1 can enhance the efficiency and accuracy of homology-directed repair (HDR) or Prime editing, and reduce off-target effects; and in combination with DNA-PK inhibitor AZD-7648 (HY-111783), exert efficient genome editing capabilities with dual pathway regulation. PolQi1 can be mainly used in gene editing research (such as CRISPR-Cas9 or Prime editing system optimization) to improve the precision editing efficiency of difficult-to-edit cells (such as primary hepatocytes and mouse embryos) [1][2][3].

Product Specifications

CAS Number

[2607139-80-8]

UNSPSC

12352005

Target

DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/polqi1.html

Purity

98.42

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CN(C1=C(C(Cl)=C(C=C1)F)F)C([C@H]2N(C3=CC(C(F)(F)F)=CC(C)=N3)C(NC2)=O)=O

Molecular Formula

C18H14ClF5N4O2

Molecular Weight

448.77

References & Citations

[1]Wimberger S, et al. Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing. Nat Commun. 2023 Aug 14;14 (1) :4761.|[2]Antoniou Panagiotis, et al. Improved nuclease-based prime editing by DNA repair modulation and pegRNA engineering. BioRxiv (2024) : 2024-02.|[3]Mentani A, et al. Prime Editing: Mechanistic Insights and DNA Repair Modulation. Cells. 2025 Feb 13;14 (4) :277.